Longboard pharmaceuticals successfully completes lp352 multiple ascending dose portion of phase 1 clinical trial in healthy volunteers, plans to initiate phase 1b/2a clinical trial

San diego, sept. 08, 2021 (globe newswire) -- longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced today that the company successfully completed the multiple ascending dose (mad) portion of a phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics (pk) and pharmacodynamics (pd) of escalating doses of lp352, an oral, centrally acting, next-generation 5-ht2c receptor superagonist, in healthy volunteers. longboard plans to advance lp352 into a phase 1b/2a efficacy trial in adult participants with dees in the first quarter of 2022 in study sites across the united states.
LBPH Ratings Summary
LBPH Quant Ranking